جستجوی استاد راهنمای دانشگاهی

Urs F. Greberمشاهده پروفایل

استاد

• Virology
• Molecular Cell Biology
• Virus-Host Interactions
• +۸ مورد دیگر

Prof. Dr. Urs F. Greber is an Ordinary Professor of Molecular Cell Biology at the Department of Molecular Life Sciences, Faculty of Mathematics and Natural Sciences, University of Zurich. His research focuses on understanding how viruses interact with host cells, particularly adenoviruses and rhinoviruses that cause human respiratory diseases. He leads the Greber Lab, which investigates viral entry mechanisms, replication processes, and the cellular responses to infection. Greber's research interests span virology, molecular cell biology, and infection mechanisms. His lab explores how viruses take control over membrane and lipid functions, cytoplasmic transport processes, and cellular metabolism to support their gene expression and progeny formation. They employ system-wide profiling, molecular cell biology approaches, light microscopy, and machine learning for image analysis to map the cell state underlying viral infections of cultured and primary human cells, including lung organoids and iPSC-derived macrophages. A key focus is understanding cell-to-cell variability in infection phenotypes and the mode-of-action of antiviral compounds. The Greber Lab has published extensively on adenovirus biology, including viral entry, uncoating, nuclear import, and assembly mechanisms. Their recent work has identified broad-spectrum antiviral compounds, elucidated alternative virus entry pathways, and developed innovative imaging and AI-based approaches for quantifying virus infectivity. Their research contributes to understanding how viruses break down host defense barriers and has implications for antiviral therapy development. Greber has supervised numerous PhD and Master's students including Cornelia Bircher, Alessandro Savi, Franziska Tomas, Alfonso Gomez-Gonzalez, Anthony Petkidis, and Dominik Olszewski. His lab has received funding from the Swiss National Science Foundation, including a grant for coronavirus research during the pandemic. The lab actively collaborates with other research groups at University of Zurich, ETH Zurich, and international institutions. Current projects include exploring how viral DNA interactions contribute to infection outcome variability, investigating adenovirus egress mechanisms, and developing high-throughput screening methods for antiviral compounds.

David Latulippeمشاهده پروفایل

استاد

• Membrane Science
• Bioprocessing
• DNA Purification
• +۴ مورد دیگر

David Latulippe is a Professor in the Department of Chemical Engineering at McMaster University. He joined McMaster in 2012 after postdoctoral work at Cornell University and a PhD at Penn State University, focusing on membrane filtration for DNA purification. His industrial experience includes roles at ZENON Environmental (now GE Water) in hollow-fiber membrane design for water treatment. Research interests include Membrane science and technology Bioprocessing of therapeutic viruses Microscale systems for biological applications Environmental engineering solutions for water treatment Current projects involve collaborations with industry partners like Ceapro and Aevitas, and the development of a biomanufacturing automation lab with Sartorius. Recent publications highlight advancements in Nanofiltration and microfiltration for viral vectors Conductive membranes for electrochemical applications Microfluidic systems for DNA analysis Environmental monitoring of biocides and microplastics Scientific recognition includes the Young Membrane Scientist Award (2014). Teaching activities focus on Fluid Mechanics (CHEMENG 2O04) and Industrial Separation Processes (CHEMENG 4M03).

Edward Hirschowitzمشاهده پروفایل

دانشیار

• Lung Cancer
• Immunotherapy
• Cancer Screening
• +۶ مورد دیگر

Edward Hirschowitz, MD is an Associate Professor in the field of Internal Medicine with significant affiliations including the Markey Cancer Center , the Cancer Research Priority Initiative , and the Translational Oncology Research Program . His academic and clinical work focuses on advancing cancer research and treatment through innovative methodologies.

Michael Danieleمشاهده پروفایل

دانشیار

• Bioelectronics Engineering
• Wearable Biosensors
• Microphysiological Systems
• +۳ مورد دیگر

Michael Daniele is an Associate Professor at North Carolina State University, jointly appointed in the Department of Electrical & Computer Engineering and the Joint Department of Biomedical Engineering . His research focuses on bioelectronics engineering, particularly in developing microsystems for monitoring, mimicking, and augmenting biological functions. He leads the @BiointerfaceLab , exploring wearable/implantable biosensors, microphysiological systems, and process analytical technologies for biomanufacturing. Education : Ph.D. in Materials Science & Engineering (Clemson University, 2012) Bachelor's in Materials Science & Engineering (Rutgers University, 2009) Research Highlights : Developing "injury-on-a-chip" models for coagulation studies Pioneering hydrogel microneedles for diagnostic devices Advancing light-controlled peptide ligands for protein purification Collaborating with Novartis on viral vector manufacturing Award Recognition : 2024 William F. Lane Outstanding Teaching Award 2019 NSF CAREER Award 2022 University Faculty Scholar Grants & Initiatives : Co-leader of the NC-Viral Vector Initiative (2023–present) NSF-funded projects in biosensor integration and biomanufacturing His work bridges engineering and medicine, with applications in gene therapy, wearable diagnostics, and precision agriculture.

Lynda Coughlanمشاهده پروفایل

دانشیار

• Vaccinology
• Immunology
• Virology
• +۶ مورد دیگر

Lynda Coughlan serves as Associate Professor in Microbiology and Immunology at the University of Maryland, Baltimore School of Medicine, with a secondary appointment at the Center for Vaccine Development and Global Health (CVD). Her research focuses on engineering next-generation adenoviral vector vaccines against respiratory pathogens including influenza, RSV, and coronaviruses, emphasizing broad cross-protection through innovative immunogen design and molecular adjuvanting. Education: BSc Microbiology, University College Cork, Ireland (2003) MS Virology, London School of Hygiene and Tropical Medicine, UK (2005) PhD Viral Gene Therapy, Barts Cancer Institute, London, UK (2009) Postdoctoral Training, University of Glasgow, UK (2009-2012) Postdoctoral Training, University of Oxford, UK (2012-2017) Postdoctoral Fellowship, Icahn School of Medicine at Mount Sinai, USA (2017-2018) Research Track Faculty, Icahn School of Medicine at Mount Sinai, USA (2018-2020) Research Focus: The Coughlan laboratory pioneers low-seroprevalence adenoviral vectors as plug-and-play platforms for universal vaccines, investigating extracellular vesicles for immunogenicity enhancement, therapeutic antibody production, and correlates of protection through comparative animal model studies. Current work spans recombinant protein immunogens, genetic adjuvanting, and vector optimization against emerging viral threats. Publication Trends: Analysis of her 13 most recent publications (2018-2024) reveals escalating emphasis on universal influenza vaccines using chimeric hemagglutinin constructs, single-dose adenoviral regimens, and extracellular vesicle-mediated immunogenicity. Post-2020 work increasingly addresses pandemic preparedness for coronaviruses and avian influenza, with molecular adjuvanting and cross-reactive immunity as unifying themes across respiratory pathogens. Scientific Awards: Graduate Women in Science Fellowship (2017) British Medical Association HC Roscoe Prize (2016) British Society for Gene and Cell Therapy Achievement Award (2016) Nuffield Department of Medicine Public Engagement Prize (2015) British Society for Immunology Communicating Immunology Grant (2015) Grants and Service: As Principal Investigator on NIH/NIAID R01AI148369 for universal influenza vaccine development and Co-PI on NIAID CIVIC contracts, she leads translational research while serving as ad-hoc reviewer for NIAID study sections. Her editorial roles include MDPI Vaccines Special Issue Editor (2020), complemented by board service for the British Society for Gene and Cell Therapy (2010-2017) and Society for General Microbiology Equality initiatives. Laboratory Structure: The Coughlan laboratory operates within the Center for Vaccine Development and Global Health, maintaining collaborative networks for preclinical-to-clinical vaccine advancement with emphasis on one-health approaches to zoonotic spillover prevention and pandemic response.

Paulina Flanneryمشاهده پروفایل

مدرس

• Microbial Pathogens
• Virology
• Molecular Diagnostics
• +۵ مورد دیگر

Dr. Paulina Flannery is a Lecturer in Molecular Biology/Biotechnology at Bangor University's Faculty of Science and Health, within the Department of Bioveterinary and Microbial Sciences. She obtained her PhD in Microbiology from the National University of Ireland, Galway, focusing on norovirus contamination in shellfish and public health implications. Her expertise includes virology, molecular diagnostics, and veterinary medicine, with a current focus on microbial pathogens and bacteriophage therapy to combat antibiotic resistance. She has authored over 35 peer-reviewed articles and collaborates internationally on viral diagnostics and biosafety training. Her research spans veterinary virology, including work at the Pirbright Institute on high-consequence animal viruses and development of molecular diagnostics. She actively contributes to the UN Sustainable Development Goals, particularly in addressing health and environmental challenges. Notable collaborations include developing high-throughput sequencing methods and training programs for exotic virus identification. Recent press coverage highlights her work on estuarine microbial dynamics and pathogen management. While currently accepting PhD students, no formal advisees are listed. Her contributions to rapid diagnostic tools for viral pathogens underscore her commitment to advancing veterinary and public health solutions.

Michael A. Barryمشاهده پروفایل

استاد

• Virology
• Gene Therapy
• Vaccine Development
• +۱۳ مورد دیگر

Michael A. Barry, Ph.D., is a Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where he holds primary and joint appointments as a Consultant in the Department of Internal Medicine (Division of Infectious Diseases), Department of Immunology, and Department of Molecular Medicine. He leads the Virology, Vector and Vaccine Engineering Laboratory, focusing on developing advanced gene therapies, viral vectors, and vaccines for challenging diseases. Institution: Mayo Clinic School: College of Medicine and Science Department: Department of Internal Medicine Academic Rank: Professor Email: barry.michael@mayo.edu Education: Ph.D., Pharmacology and Toxicology, Dartmouth College Postgraduate Trainee, University of Texas Southwestern Medical Center B.S., Chemistry, Nebraska Wesleyan University Dr. Barry’s research centers on virology, gene therapy, and vaccine engineering. His lab develops in vivo molecular and viral therapies using adenovirus, adeno-associated virus (AAV), and lipid nanoparticles. Key areas include gene therapy for metabolic diseases like propionic acidemia and Alport syndrome, gene-based vaccines for HIV, influenza, Zika, and SARS-CoV-2, and oncolytic immunotherapy viruses for cancer. His team engineered a single-cycle adenovirus COVID-19 vaccine tested in Phase 1 trials (NCT04839042) and is advancing CRAd657-CD40L for melanoma clinical trials in 2025. They also work on basic virology of Ebola and pandemic influenza, leveraging findings for therapeutic development. His recent publications highlight innovations in adenoviral vector generation (FastAd toolkit), mucosal vaccine delivery, structural insights into adenovirus-blood interactions, and AAV-mediated therapies for musculoskeletal and gastrointestinal conditions. These works reflect a strong trend in translational virology and targeted therapeutics. Scientific Awards: None explicitly mentioned in the provided text. Advising and Grants: Dr. Barry has secured substantial grant funding, including from the National Institute of Allergy and Infectious Diseases (NIAID) and Congressionally Directed Medical Research Programs, for projects such as single-cycle SARS-CoV-2 vaccines, oncolytic therapies for kidney cancer, Ebola virus pathogenesis, mucosal HIV vaccines, and Zika virus vaccines. He mentors trainees and supports postdoctoral fellowships, though specific student names are not listed. His lab fosters collaboration across Mayo Clinic centers, including the Center for Individualized Medicine, Center for Regenerative Biotherapeutics, and Mayo Clinic Comprehensive Cancer Center. Labs and Teams: He directs the Virology, Vector and Vaccine Engineering Laboratory, which focuses on cell-targeted delivery, vector purification, mucosal vaccination, polymer shielding of vectors, and optical imaging for tracking. The lab employs high-throughput screening, genetic engineering, and animal imaging to optimize vector specificity and reduce off-target effects.

Masataka Suzukiمشاهده پروفایل

دانشیار

• Cancer Immunotherapy
• Gene Therapy
• CAR-T Cell Therapy
• +۳ مورد دیگر

Masataka Suzuki is an Associate Professor at Baylor College of Medicine, affiliated with the Center for Gene Therapy and the Dan L Duncan Comprehensive Cancer Center. His research focuses on cancer immunotherapy, particularly combining oncolytic virotherapy with CAR-T cell therapy to target solid tumors. He explores strategies such as cytokine delivery, checkpoint inhibitors, and BiTE molecules to enhance therapeutic efficacy while evaluating tumor immune microenvironments using humanized mouse models. His work emphasizes translational research, including preclinical and clinical studies of ultralow-dose adenoviral vectors. Key projects include in vivo CAR-T cell generation using viral vectors and investigating heterogeneous tumor responses to combination therapies. Publications highlight advancements in modulating immune systems to combat pancreatic tumors and metastatic cancers, demonstrating expertise in viral vector engineering and immunotherapeutic synergy. While no awards or grants are explicitly listed, his contributions to the field are evident through his active research projects and peer-reviewed publications.

Richard Greenbergمشاهده پروفایل

استاد

• Vaccine Development
• Infectious Diseases
• HIV/AIDS Research
• +۳ مورد دیگر

Dr. Richard Greenberg is a Professor of Internal Medicine with a focus on Infectious Diseases at the University of Kentucky. His career spans over three decades, with expertise in vaccine development, HIV/AIDS research, and clinical trials for antifungal therapies. He holds academic appointments in the School of Medicine and collaborates with institutions like the National Institutes of Health (NIH) and pharmaceutical companies on vaccine trials for diseases such as hepatitis, HIV, pneumococcal pneumonia, and smallpox. His research emphasizes translational medicine, particularly in vaccine efficacy, immune response characterization, and antifungal drug efficacy in immunocompromised patients. Dr. Greenberg has led numerous clinical trials for novel vaccines (e.g., oral cholera, pandemic influenza) and contributed to pivotal studies on zoster (shingles) vaccine safety and pneumococcal conjugate vaccines in elderly populations. His work bridges academia and industry, addressing global health challenges through rigorous clinical research. Education : Medical Degree: Tufts University School of Medicine Residency: Indiana University Medical Center and Louisiana State University Medical School Fellowship: Louisiana State University Medical Center NIH Training Fellowship: University of Virginia Medical Center Research Interests : Dr. Greenberg’s research centers on: Vaccine development for infectious diseases (e.g., HIV, influenza, smallpox) Immunocompromised patient care, particularly in histoplasmosis and cryptococcosis Antifungal therapy optimization (e.g., isavuconazonium for mucormycosis) HIV-associated complications and antiretroviral drug effects Clinical trials for novel drug delivery systems like MucoJet oral vaccines Grants & Collaborations : His work has been funded by NIH (NIAID), industry partnerships (e.g., Bavarian Nordic, GSK), and DoD for defense-related vaccines (e.g., botulism, plague). He serves as a sub-investigator for NIH-funded VTEU trials and leads vaccine efficacy studies at the University of Kentucky’s clinical research unit. Labs & Teams : Collaborates with the university’s infectious disease research group and biostatistics core, focusing on clinical trial design and biomarker analysis for vaccine responses.

• Virology
• HIV Research
• Vaccine Development
• +۳ مورد دیگر

Stephen Dewhurst, Ph.D., is Vice President for Research and Chief Research Officer at the University of Rochester (UR) and Vice Dean for Research at the UR School of Medicine and Dentistry (SMD). He holds a professorship in the Department of Microbiology and Immunology (SMD). His administrative roles include former department chair (2009–2021), SMD Senior Associate Dean for Basic Research (2007–2009), and codirector of UR’s Center for AIDS Research (2008–2020). Dr. Dewhurst’s research focuses on virology, with 30+ years’ experience including HIV neuropathogenesis, vaccine development, and innate immune responses. He leads NIH-funded programs in graduate education and Deaf postdoctoral training. His mentorship has guided 29 Ph.D. students, 16 postdoctoral fellows, and >100 undergraduates, earning awards like the William H. Riker Award (2008) for graduate education. Key scientific contributions include HIV humanized mouse models, antiviral therapeutics, and MLK inhibitors for neuroinflammation. His patents span viral vectors, integrin-binding monobodies, and influenza vaccines. Awards include membership on NIH study sections (e.g., HIV Immunopathogenesis) and editorial roles in virology journals.

Hu Yangمشاهده پروفایل

استاد

• Biomaterials
• Nanotechnology
• Drug Delivery
• +۷ مورد دیگر

Dr. Hu Yang is the Linda and Bipin Doshi Chair and Professor of Chemical and Biochemical Engineering at Missouri University of Science and Technology , serving as Department Chair and Director of the Center for Biomedical Research (CBR). He previously held the Qimonda Endowed Chair at Virginia Commonwealth University (VCU). His research focuses on nanotechnology-driven biomedical solutions, including drug delivery systems, dendrimer engineering, and treatments for cancer, glaucoma, and atherosclerosis. He has secured over $10M in research funding, including NSF and Coulter Awards, and holds five patents. Education: B.S. in Polymer Science from Sichuan University (1998), Ph.D. in Chemical Engineering from the University of Akron (2004), and postdoctoral training in pharmaceutical sciences at the University of Wisconsin-Madison. Research Interests: Biomaterials, nanotechnology, targeted drug delivery, gene therapy, ocular disease treatments, and pharmaceutical engineering. Key projects include ROS-responsive nanoassemblies for atherosclerosis, cancer cell membrane-derived vaccines, and dendrimer-based hydrogels for retinoblastoma treatment. Publications: Over 120 peer-reviewed articles, with recent work in Advanced Science , Biomacromolecules , and Journal of Agricultural and Food Chemistry . Themes include nanoparticle analysis in plant tissues, glaucoma therapy, and neuroinflammation studies. Awards: NSF CAREER Award (2010), Coulter Young Investigator Award (2009), and recognition as a top 2% cited scientist (Stanford, 2024). Grants & Leadership: Primary investigator on $5.5M NIH/NSF grants. Editorial roles include Materials Express and Smart Materials in Medicine . Lab: Drug and Gene Delivery Laboratory at Missouri S&T. Additional Roles: Member of the Massey Cancer Center (VCU), grant reviewer for NIH/NSF, and advocate for diversity in STEM education.

John T. Schillerمشاهده پروفایل

استاد پژوهش

• Cancer Biology
• Virology
• Immunology
• +۳ مورد دیگر

John T. Schiller is a Senior Investigator and NIH Distinguished Investigator at the Laboratory of Cellular Oncology, National Cancer Institute (NCI), NIH. He co-developed the foundational HPV prophylactic vaccines (Cervarix, Gardasil) and leads research on papillomavirus biology, vaccine innovation, and capsid-based cancer therapies. His roles include Deputy Chief of the lab and Head of the Neoplastic Disease Section. Education: B.S. in Molecular Biology, University of Wisconsin-Madison (1975) Ph.D. in Microbiology, University of Washington (1982) Research Focus: Molecular mechanisms of HPV virion assembly and infection, development of prophylactic/therapeutic vaccines, and tumor-targeting HPV capsids. His work leverages VLPs and pseudovirions for translational studies, exploring tissue-resident T cells for STI protection and cancer immunotherapy. Scientific Awards: 2007 Service to America Medal – Federal Employee of the Year 2011 Albert Sabin Gold Medal Award 2011 AACR-American Cancer Society Award for Research Excellence 2014 National Medal of Technology and Innovation 2017 ASM Joseph Public Health Award Team: Collaborates with Staff Scientists (e.g., Nicolas Çuburu, Ph.D.), Senior Associate Scientists (e.g., Patricia M. Day, Ph.D.), and other researchers in the NCI/CCR. The lab focuses on virology, immunology, and clinical applications of HPV-based technologies.

• Gene Therapy
• Virology
• Molecular Biology
• +۳ مورد دیگر

Associate Professor Leszek Lisowski is affiliated with the Children's Medical Research Institute (CMRI) at the University of Sydney. He holds the roles of Conjoint Senior Lecturer and Associate Professor, focusing on viral vector development for gene therapy applications, particularly using adeno-associated viruses (AAV). His research emphasizes enhancing AAV tropism for liver, cardiac, and CNS targets, with a strong focus on translational medicine. Key research areas include AAV capsid engineering, optimization of liver and cardiac gene delivery, and applications in neurodegenerative diseases like amyotrophic lateral sclerosis. He leads projects funded by grants such as the NHMRC Ideas Grant and the Cure4 Cystic Fibrosis Foundation. Current research student Ahmad Hammoud is investigating novel AAV capsids for cardiac gene therapy. His work spans collaborations in optogenetics, CAR-T cell engineering, and liver perfusion models. Notable publications highlight advancements in AAV genome structure, liver fibrosis impact on gene transfer, and hydrogel-mediated viral vector protection. His contributions bridge virology, molecular biology, and clinical translation, aiming to address unmet needs in genetic disorders and cancer therapies.

Phoebe L. Stewartمشاهده پروفایل

استاد

• Cryo-Electron Microscopy
• Structural Biology
• Virology
• +۳ مورد دیگر

Phoebe L. Stewart is a Professor in the Department of Pharmacology at the School of Medicine, Case Western Reserve University. She also serves as Vice Chair of Educational Programs in the Department of Pharmacology. Her research focuses on applying cryo-electron microscopy to study viral structures and their interactions with host factors, particularly adenovirus and engineered oncolytic viruses. Dr. Stewart's work integrates multiple structural methods including X-ray crystallography, NMR, and molecular dynamics to understand viral mechanisms and develop therapeutic strategies against cancer. She holds affiliations with the Cleveland Center for Membrane and Structural Biology and the Case Comprehensive Cancer Center. Education: AB in Biochemistry (Harvard University), PhD in Chemistry (University of Pennsylvania). Postdoctoral training included cryo-EM at the Wistar Institute and EMBL Heidelberg. Research interests emphasize viral structure, host-pathogen interactions, and oncolytic virotherapy. Notable projects include structural analysis of adenovirus-complement interactions and designing viruses that evade innate immunity for systemic cancer therapy. Publications span structural virology, cryo-EM applications, and nanoparticle design. Her lab collaborates on engineering viral vectors for targeted drug delivery and immune modulation.

Richard G. Vileمشاهده پروفایل

استاد

• Cancer Immunotherapy
• Oncolytic Virotherapy
• Chimeric Antigen Receptor (CAR) T-cell Therapy
• +۷ مورد دیگر

Richard G. Vile, Ph.D., is a Professor of Immunology at Mayo Clinic in Rochester, Minnesota, with primary appointments as Consultant in the Department of Molecular Medicine and joint appointment in the Department of Immunology. He is also the Richard M. Schulze Family Foundation Professor, an honor awarded in 2008. His research is centered on developing innovative cancer immunotherapies, particularly through oncolytic virotherapy, CAR T-cell therapy, and combination strategies with radiotherapy. Dr. Vile’s research focuses on stimulating antitumor immune responses using murine immune-competent models and syngeneic tumors. His work spans multiple cancer types, including melanoma, prostate cancer, glioma, brain metastases, and hepatocellular carcinoma. A major innovation from his lab is engineering vesicular stomatitis virus (VSV) to express tumor antigen libraries, enhancing immune recognition and destruction of tumors. His recent publications reveal a strong emphasis on enhancing CAR T-cell efficacy, overcoming immune evasion, and combining oncolytic viruses with checkpoint inhibitors. These studies highlight his leadership in advancing immunovirotherapeutic strategies for solid tumors, particularly through genetic engineering of viral vectors and immune cell therapies. The Richard M. Schulze Family Foundation Professor (2008) Dr. Vile has secured substantial research funding from the National Cancer Institute and the National Institute of Allergy and Infectious Diseases, supporting active projects into 2026. He is directly involved in clinical translation, including an ongoing trial for hepatocellular carcinoma using a VSV-based therapy. He mentors a research team and collaborates internationally, particularly with researchers in the UK. His lab is part of the Mayo Clinic Comprehensive Cancer Center and the David F. and Margaret T. Grohne Cancer Immunology and Immunotherapeutics Program.